Ostendum LOAC Nanodevices are Produced with SCIENION’s sciFLEXARRAYER SX
SCIENION AG has announced that Ostendum R&D B.V., a Dutch company focused on the development and production of fast, highly sensitive, portable, easy-to-use and cost-effective biosensors, is using SCIENION’s sciFLEXARRAYER to print their unique Lab-on-a-Chip nanodevices.
Ostendum has developed a proprietary technology for the Lab-on-chip nanodevices market which has been awarded a number of awards, most recently the 2013 Frost & Sullivan Award for Technology Innovation Leadership. The technology includes both novel Lab-on-a-Chip nanodevices and an integral optical detection platform.
“We were able to experience and see the advantages of SCIENION’s sciFLEXARRAYER technology at the laboratory of Dr. Aart van Amerongen of the Biomolecular Sensing & Diagnostics group of Wageningen UR (collaborative group conducting food research as a core area)”, says Ostendum’s CEO Dr. Paul H. J. Nederkoorn. “We came to the conclusion that the sciFLEXARRAYER non-contact dispenser would be the best solution to precisely and accurately spot antibodies onto our nanodevices. After further test runs with excellent results in SCIENION’s facilities, we opted for the SX model which enables us to complete any R&D processes and to scale up for production. This compact and fully-automated system will allow high throughput production of our chips. Furthermore it is suitable for our future activities in developing higher multiplexed chips, whereas we may increase the number of channels from currently four to up to eight channels per device.”
Dr. Holger Eickhoff, CEO of SCIENION AG, states: “With its fully portable Lab-on-a-Chip system Ostendum has developed a unique technology which offers tailor-made solutions for present needs in healthcare diagnostics as well as other areas such as food and water analytics or biological warfare testing. This portable point-of-care diagnostics technology for viruses and bacteria may play an important role in future control of epidemics or biohazards. Furthermore, point-of-care diagnostics of biomarkers will enable healthcare providers with vital information to act quickly and adequately. We are very happy that Ostendum decided for the sciFLEXARRAYER SX to produce their LOC nanodevices. I am looking forward to a productive collaboration with this innovative company.”
The potential of Ostendum’s technology for changing the healthcare landscape is also reflected by recent investments of two Dutch health insurers. In May 2013, the company raised venture capital from Achmea, the largest health insurer of the Netherlands, and from de Friesland Zorgverzekeraar.
Please meet us at: Molecular Med TRI-CON, February 10-12, 2014 in San Francisco, CA, USA; booth 522. Register now for the 1st Sony DADC & SCIENION Symposium “Ideas at the point of commercialization”, March 31, 2014 in Salzburg, Austria. The agenda is available at www.scienion.com.